I am attempting to reestablish Turning Hard Times into Good Times a podcast that aired from 2009 to 2023 on the Voice American Business channel.
In this podcast Chen Lin talks about an exciting biotech stock that appears to have a promising drug to enable damaged spinal cords to self repair. The company in question is in Phase II trials and there are some unofficial rumors of success in humans after establishing that the drug was effective in repairing damaged spinal cord tissue in mice.
Chen also provided his thought on the equity markets, uranium, oil and gas and how the dramatic rise in solar panels is extremely bullish for silver. Regarding gold, Chen thinks it may be range bound until the autumn assuming China continues to hold of on the aggressive purchase of those metals then.
Please listen to Chen’s interesting insights. Of special interest to me is Chen’s comments on the biotech company conducting trials for spinal cord repair.
Best wishes,
Jay Taylor
%26stroke%3Dnone%26strokeWidth%3D3.6){kind=small}
